gyrA Gene Mutation Conferring Phenotypic Cross-Resistance among Fluoroquinolones (Ofloxacin, Levofloxacin and Gatifloxacin) in Multidrug Resistant Mycobacterium tuberculosis Strains Isolated from Pulmonary MDR-TB Patients in Bangladesh
Background and objectives: Fluoroquinolones (FLQs) are an essential component of multidrug resistant-tuberculosis (MDR-TB) treatment regimen but unfortunately the emergence of FLQ resistant MDR-TB cases is challenging the current MDR-TB treatment regimen. FLQ resistance is mainly caused by gyrA gene mutation and phenotypic cross-resistance may occur among the different FLQs. A limited number of data exists regarding the cross-resistance phenomenon among FLQs and it appears that resistance to the present class representative FLQ, ofloxacin (OFX), may or may not correlate with complete cross-resistance to other FLQs. So the study was designed to observe if gyrA gene mutations confer to the phenotypic cross-resistance among FLQs [OFX, Levofloxacin (LFX) and Gatifloxacin (GFX)] tested. Methodology: Sputum samples from 68 diagnosed pulmonary MDR-TB cases were collected. All samples were subjected to Multiplex Real-time PCR for the detection of gyrA gene mutations and conventional culture on Lowenstein-Jensen (L-J) media followed by drug sensitivity testing (DST) of culture isolates (MDR-TB strains) by indirect proportion method for the detection of phenotypic resistance pattern to OFX, LFX and GFX. Results: Out of the 68 MDR-TB sputum samples 13 (19.11%) had MDR-TB bacilli with mutations in the gyrA gene and 11(16.18%) of the MDR-TB culture isolates were found to have resistance to FLQs by DST. The study observed that 11 MDR-TB samples with gyrA gene mutations showed complete phenotypic cross-resistance among OFX, LFX and GFX. Conclusion: This study found that mutation in the gyrA gene of the MDR-TB bacilli results in the complete cross-resistance among the FLQs (OFX, LFX and GFX) tested. It is therefore of utmost importance to carry out the base line resistance and cross-resistance tests for the individual FLQs prior to initiating the treatment of MDR-TB cases in Bangladesh for successful clinical outcomes.
References
[1]
Gay, J.D., De Young, D.R. and Roberts, G.D. (1984) In Vitro Activities of Norfloxacin and Ciprofloxacin against Mycobacterium tuberculosis, M. avium Complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrobial Agents and Chemotherapy, 26, 94-96. https://doi.org/10.1128/AAC.26.1.94
[2]
Mohapatra, P.R. (2004) Fluoroquinolones in Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 170, 920-921.
https://doi.org/10.1164/ajrccm.170.8.951
[3]
Tasnim, T., Tarafder, S., Alam, F.M., Sattar, H. and Kamal, S.M. (2018) Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh. Journal of Tuberculosis Research, 6, 199-206. https://doi.org/10.4236/jtr.2018.63018
[4]
World Health Organization (2014) Global Tuberculosis Report 2014. WHO/HTM/TB/ 2014.08. WHO, Geneva. http://www.who.int/tb/publications/global_report/en/
[5]
Kim, H., Nakajima, C., Yokoyama, K., Rahim, Z., Kim, Y.U., Oguri, H. and Suzuki, Y. (2011) Impact of the E540V Amino Acid Substitution in GyrB of Mycobacterium tuberculosis on Quinolone Resistance. Antimicrobial Agents and Chemotherapy, 55, 3661-3667. https://doi.org/10.1128/AAC.00042-11
[6]
Levine, C., Hiasa, H. and Marians, K.J. (1998) DNA Gyrase and Topoisomerase IV: Biochemical Activities, Physiological Roles during Chromosome Replication, and Drug Sensitivities. Biochimicaet Biophysica Acta (BBA)—Gene Structure and Expression, 1400, 29-43. https://doi.org/10.1016/S0167-4781(98)00126-2
[7]
Cole, S., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry III, C.E. and Tekaia, F. (1998) Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence. Nature, 393, 537-544. https://doi.org/10.1038/31159
[8]
Maruri, F., Sterling, T.R., Kaiga, A.W., Blackman, A., van der Heijden, Y.F., Mayer, C., Cambau, E. and Aubry, A. (2012) A Systematic Review of Gyrase Mutations Associated with Fluoroquinolone-Resistant Mycobacterium tuberculosis and a Proposed Gyrase Numbering System. Journal of Antimicrobial Chemotherapy, 67, 819-831. https://doi.org/10.1093/jac/dkr566
[9]
Malik, S., Willby, M., Sikes, D., Tsodikov, O.V. and Posey, J.E. (2012) New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations. PloS One, 7, e39754.
https://doi.org/10.1371/journal.pone.0039754
[10]
Pantel, A., Petrella, S., Veziris, N., Brossier, F., Bastian, S., Jarlier, V., Mayer, C. and Aubry, A. (2012) Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 56, 1990-1996. https://doi.org/10.1128/AAC.06272-11
[11]
Jabeen, K., Shakoor, S., Chishti, S., Ayaz, A. and Hasan, R. (2011) Fluoroquinolone-Resistant Mycobacterium tuberculosis, Pakistan, 2005-2009. Emerging Infectious Diseases, 17, 564-566. https://doi.org/10.3201/eid1703.100957
[12]
Ziganshina, L.E., Vizel, A.A. and Squire, S.B. (2005) Fluoroquinolones for Treating Tuberculosis. Cochrane Database of Systematic Reviews, Hoboken.
[13]
Sirgel, F.A., Warren, R.M., Streicher, E.M., Victor, T.C., van Helden, P.D. and Böttger, E.C. (2012) gyrA Mutations and Phenotypic Susceptibility Levels to Ofloxacin and Moxifloxacin in Clinical Isolates of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 67, 1088-1093. https://doi.org/10.1093/jac/dks033
[14]
Yew, W.W., Chan, C.K., Leung, C.C., Chau, C.H., Tam, C.M., Wong, P.C. and Lee, J. (2003) Comparative Roles of Levofloxacin and Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis: Preliminary Results of a Retrospective Study from Hong Kong. Chest, 124, 1476-1481. https://doi.org/10.1378/chest.124.4.1476
[15]
GLI (2014) Mycobacteriology Laboratory Manual. Global Laboratory Initiative a Working Group of the Stop TB Partnership, Geneva, Switzerland.
http://www.who.int/tb/laboratory/mycobacteriology-laboratory-manual.pdf
[16]
WHO (2012) Global TB Programme: Updated Interim Critical Concentrations for First-Line and Second-Line DST (as of May 2012).
http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table
_1st%20and%202nd%20line%20drugs.pdf
[17]
Singhal, R., Reynolds, P.R., Marola, J.L., Epperson, L.E., Arora, J., Sarin, R., Myneedu, V.P., Strong, M. and Salfingera, M. (2016) Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India. Journal of Clinical Microbiology, 54, 2298-2305.
https://doi.org/10.1128/JCM.00670-16
[18]
Chen, J., Peng, P., Du, Y., Ren, Y., Chen, L., Rao, Y. and Wang, W. (2017) Early Detection of Multidrug- and Pre-Extensively Drug-Resistant Tuberculosis from Smear-Positive Sputum by Direct Sequencing. BMC Infectious Diseases, 1, 1-7.
[19]
Dooley, K.E., Golub, J., Goes, F.S., Merz, W.G. and Timothy, S.R. (2002) Empiric Treatment of Community-Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis. Clinical Infectious Diseases, 34, 1607-1612.
https://doi.org/10.1086/340618
[20]
Yew, W.W., Chan, C.K., Chau, C.H., Tam, C.M., Leung, C.C., Wong, P.C. and Lee, J. (2000) Outcomes of Patients with Multidrug-Resistant Pulmonary Tuberculosis Treated with Ofloxacin/Levofloxacin-Containing Regimens. Chest, 117, 744-751.
https://doi.org/10.1378/chest.117.3.744
[21]
Von Groll, A., Martin, A., Jureen, P., Hoffner, S., Vandamme, P., Portaels, F., Palomino, J.C. and da Silva, P.A. (2009) Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB. Antimicrobial Agents and Chemotherapy, 53, 4498-4500. https://doi.org/10.1128/AAC.00287-09
[22]
Mamatha, H.G. and Shanthi, V. (2018) Baseline Resistance and Cross-Resistance among Fluoroquinolones in Multidrug-Resistant Mycobacterium tuberculosis Isolates at a National Reference Laboratory in India. Journal of Global Antimicrobial Resistance, 12, 5-10. https://doi.org/10.1016/j.jgar.2017.08.014
[23]
Willby, M., Sikes, R.D., Malik, S., Metchock, B. and Posey, J.E. (2015) Correlation between GyrA Substitutions and Ofloxacin, Levofloxacin, and Moxifloxacin Cross-Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 59, 5427-5434. https://doi.org/10.1128/AAC.00662-15
[24]
Yin, X. and Yu, Z. (2010) Mutation Characterization of gyrA and gyrB Genes in Levofloxacin-Resistant Mycobacterium tuberculosis Clinical Isolates from Guangdong Province in China. Journal of Infection, 61, 150-154.
https://doi.org/10.1016/j.jinf.2010.05.001
[25]
Kam, K.M., Yip, C.W., Cheung, T.L., Tang, H.S., Leung, O.C. and Chan, M.Y. (2006) Stepwise Decrease in Moxifloxacin Susceptibility amongst Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis: Correlation with Ofloxacin Susceptibility. Microbial Drug Resistance, 12, 7-11.
[26]
Cabral, J.H.M., Jackson, A.P., Smith, C.V., Shikotra, N., Maxwell, A. and Liddington, R.C. (1997) Crystal Structure of the Breakage-Reunion Domain of DNA gyrase. Nature, 388, 903-906. https://doi.org/10.1038/42294
[27]
Piton, J., Petrella, S., Delarue, M., Andre-Leroux, G., Jarlier, V., Aubry, A. and Mayer, C. (2010) Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase. PLoS ONE, 5, e12245.
https://doi.org/10.1371/journal.pone.0012245
[28]
Tretter, E.M., Schoeffler, A.J., Weisfield, S.R. and Berger, J.M. (2010) Crystal Structure of the DNA gyrase GyrA N-Terminal Domain from Mycobacterium tuberculosis. Proteins: Structure, Function, and Bioinformatics, 78, 492-495.
https://doi.org/10.1002/prot.22600
[29]
Aubry, A., Veziris, N., Cambau, E., Truffot-Pernot, C., Jarlier, V. and Fisher, L.M. (2006) Novel gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis: Functional Analysis of Mutant Enzymes. Antimicrobial Agents and Chemotherapy, 50, 104-112.
